37degrees

Executive Summary

37degrees is a San Francisco-based life science technology company developing next-generation, portable systems for cell and tissue culture. Founded in 2017, the company integrates incubation, perfusion, and live-cell imaging into a single platform, leveraging AI and machine learning for real-time biological data processing and analysis. This approach aims to revolutionize traditional cell culture workflows by providing a compact, scalable solution that can be used across research labs, biopharma, and potentially clinical settings. By automating key processes and enabling continuous monitoring, 37degrees’ technology could significantly accelerate drug discovery, personalized medicine, and regenerative medicine research. The portable cell culture market is growing rapidly as researchers demand more efficient, reproducible, and high-throughput systems. 37degrees is well-positioned to capture value in this space, but the company remains early-stage with no disclosed funding rounds or partnerships. The platform’s AI-driven analytics offer a competitive edge, but validation and commercial traction are still needed. If the company can secure strategic partnerships or funding, it could emerge as a key player in the digital health and AI-enabled lab equipment market. However, execution risks and competition from established players remain significant.

Upcoming Catalysts (preview)

• Q3 2026Commercial product launch or beta release35% success
• Q4 2026Strategic partnership with biopharma or research institution30% success
• Q1 2027Series A funding announcement50% success